Part:BBa_K5083002
Bimagrumab
Bimagrumab is a humanized monoclonal antibody that binds to type II receptor on muscle cell surfaces. It is primarily used to treat muscle wasting diseases and has been evaluated in multiple clinical trials. Bimagrumab targets ActRIIA and ActRIIB, which play crucial roles in mediating myostatin and activin signaling pathways, thereby preventing muscle wasting and increasing skeletal muscle density. We demonstrated through Western blotting that Bimagrumab can be expressed in Escherichia coli BL21.
Description
Considering that obesity often leads to muscle loss during weight loss, which in turn can cause a range of health problems, we have chosen to express Bimagrumab in probiotics. This approach aims to help patients prevent muscle loss while losing weight. Bimagrumab, derived from Homo sapiens, can block the ActRIIA/ActRIIB signaling pathways, thereby preventing muscle wasting.
Usage and Biology
We utilized the ribosome binding site from the iGEM part library (BBa_B0034) followed by the sequence fragment of Bimagrumab. To express Bimagrumab, we used a constitutive promoter (BBa_J23100) and a strong terminator (BBa_B0015). Finally, we employed the pET23b vector as the plasmid and transformed it into Escherichia coli BL21.
Fig 1.genetic circuit diagram
Potential application directions
Fig 2.Western blotting validation of Bimagrumab expression.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
None |